Age at diagnosis
|
43
|
54 (died in 2019)
|
55 (died in 2020)
|
70 (died in 2020)
|
57 (died in 2014)
|
Sex
|
M
|
M
|
M
|
F
|
M
|
Operation time
|
2016
|
2015
|
None
|
2016
|
2003
|
Thymoma histology
|
A
|
AB
|
B2
|
AB
|
AB
|
B cells (5–18%)
|
3.1↓
|
0.5↓
|
0.6↓
|
3.7↓
|
4.4↓
|
T cells (60–79%)
|
93.4↑
|
93.1↑
|
88.3↑
|
93.6↑
|
87.8↑
|
CD4 + T cell (34–52%)
|
17.5↓
|
13.7↓
|
8.4%↓
|
30.9↓
|
32.1↓
|
CD8 + T cell (21–39%)
|
65.4↑
|
63.5↑
|
74.7%↑
|
57.3↑
|
49.8↑
|
IgG (7.0–16.0 g/L or 7.51–15.6 g/L)
|
0.51↓
|
1.59↓
|
1.34↓
|
1.9↓
|
0.82↓
|
IgA (0.7–4.0 g/L or 0.82–4.53 g/L)
|
< 0.0667↓
|
< 0.26↓
|
0.25↓
|
< 0.0667↓
|
0.13↓
|
IgM (0.4–2.3 g/L or 0.46–3.04 g/L)
|
0.15↓
|
< 0.17↓
|
< 0.17↓
|
0.09↓
|
0.08↓
|
Clinical symptoms
|
Cough, expectoration, chest tightness, diarrhea
|
Cough, expectoration, fever, diarrhea
|
Skin and mucosal abscesses, cough, dyspnea
|
Cough, diarrhea, abdominal discomfort
|
Fever, cough
|
Main location of infection
|
Respiratory tract
|
Respiratory tract
|
Respiratory tract
|
Respiratory tract, intestinal tract
|
Respiratory tract
|
Severity of infection
|
Mild
|
Severe
|
Severe
|
Mild to Severe
|
Severe
|
Main comorbiditiesa
|
Bronchiectasis, pneumonia
|
Pneumonia, bronchiectasis, COPD, ARDS, respiratory failure
|
Pericardial placeholder, COPD, interstitial pneumonia
|
Oral lichen planus, intestinal infection, urinary tract infection
|
Interstitial pneumonia, pulmonary tuberculosis
|
Pathogenb
|
C. difficile
|
CMV, RuV, CVB, Aspergillus, SPn, ECl, Cal, Aba
|
CMV, Pc
|
CMV, Hp
|
Cal, TB
|
Treatmentc
|
IVIG, Antibiotic
|
IVIG, ALB, Antibiotic, Antifungal, Methylprednisolone
|
IVIG, Antibiotic, Methylprednisolone
|
IVIG, ALB, Antibiotic
|
IVIG, Antibiotic, Methylprednisolone, Antiviral
|
Radiotherapy
|
No
|
No
|
Yes
|
No
|
Yes
|
Chemotherapy
|
No
|
No
|
Yes
|
No
|
No
|
Live status
|
Survived
|
Died
|
Died
|
Died
|
Died
|
Cause of death
|
None
|
Lung infection, coronary heart disease
|
Lung infection
|
Severe pneumonia, septic shock and respiratory failure
|
Septic shock, multiple organ failure
|